Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers.

S5 ), erlotinib used as a single agent was not sufficient to reduce EGFR activation at 6 and 24 hours postadministration, whereas the erlotinib-alisertib combination produced highly significant reduction.

also in 132,142 other papers